TransMedics Posts Record Q3 2026 Revenue, Raises Full-Year Guidance
As seen on the 24/7 Wall St. homepage on November 5, 2026.
TransMedics raised full-year revenue guidance to $764 million to $774 million after its biggest quarter ever, before PAD Aviation contributes anything. Liver and heart volume through the National OCS Program is still compounding, and ENHANCE Heart Part B, DENOVO Lung and an OCS Kidney human study are all queued for 2027.
Continue ReadingShow less
TransMedics Group reported $203.0 million in revenue for the third quarter of 2026, beating the $178.1 million consensus estimate by 14% and marking a 41.1% increase from a year earlier. Adjusted EPS of $0.51 beat the $0.29 estimate by 74%, extending a streak of double-digit earnings surprises that began in earnest after a soft Q4 2024.
The headline numbers were powered by rising liver and heart case volumes through the National OCS Program, with service revenue climbing 59.6% year over year. PAD Aviation, the organ transplant air logistics business in which TransMedics made a strategic investment on July 1, 2026, contributed $9.4 million of charter services revenue. Even stripping that out, organic revenue grew 34.6%, and organic service revenue grew 42.8%.
GAAP net income fell to $17.1 million from $24.3 million a year ago, as operating expenses, interest costs and a tax provision all expanded materially. Research, development and clinical trial expense alone rose to $29.2 million from $15.3 million year over year, reflecting heavy investment in the pipeline.
Sponsored
Management raised full-year 2026 revenue guidance to $764 million to $774 million including PAD Aviation, implying 26% to 28% growth over fiscal 2025. Excluding PAD Aviation, the range moved to $750 million to $760 million from a prior $737 million to $757 million. CEO Waleed Hassanein described the quarter as "the strongest in TransMedics' history" and noted it was achieved "despite typical third quarter seasonality and before any contribution from ENHANCE Part B or DENOVO."
Looking to 2027, the company has three clinical programs queued. The FDA approved IDE applications for ENHANCE Heart Part B and DENOVO Lung trials in October 2026, with the CHOPS device serving as the control arm in both. OCS Kidney remains on track for first-in-human clinical experience in the second half of 2027, targeting what management called the largest transplant market. TransMedics also plans to launch OCS NOP in Italy, the Netherlands and Belgium, building on a first European transplant logistics win in Italy using PAD Aviation.
Mentioned: TMDX